Frank Rimerman Advisors’s Genmab GMAB Stock Holding History

Frank Rimerman Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,580	Closed	-$203K	–	613
2025 Q4	$203K	Buy	+6,580	New	+$205K	0.01%	590

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Frank Rimerman Advisors's GMAB Position: Q1 2026 in Review

Frank Rimerman Advisors sold out of Genmab (GMAB) in Q1 2026, closing a stake of 6,580 shares — an estimated $203K sold.

Frank Rimerman Advisors first reported a position in GMAB in Q4 2025 and held it in 1 quarter. The position peaked at $203K in Q4 2025. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Frank Rimerman Advisors reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
Frank Rimerman Advisors sold 6,580 Genmab shares in Q1 2026, an estimated $203K.
Frank Rimerman Advisors first reported a position in Genmab in Q4 2025 and held it in 1 quarter.
Frank Rimerman Advisors's Genmab position peaked at $203K in Q4 2025.
275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Frank Rimerman Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.